CD8A and neoplasm: To assess whether changes in the efficacies of the different treatment regimens correlate to differences in the immune cell composition of the tumor after treatment, we quantified the amount of tumor-infiltrating effector T cells (CD8+ CD44+) on day 7 after tumor IR (Fig. 4G).